呼吸器疾患治療薬の世界市場:喘息、COPD、アレルギー性鼻炎、肺高血圧症、嚢胞性繊維症、IPF...市場調査レポートについてご紹介

【英文タイトル】Global Respiratory Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview: Respiratory diseases
• Asthma
• COPD
• Allergic rhinitis
• Pulmonary hypertension
• Cystic fibrosis
• IPF
• US FDA-approved respiratory drugs

PART 06: Pipeline analysis
• Information on some pipeline candidates

PART 07: Market landscape
• Five forces analysis

PART 08: Market segmentation by class of drugs
• Bronchodilators
• Leukotriene antagonists
• Mast cell stabilizers
• Immunosuppressants
• Combination of LABA/ICS
• Tyrosine kinase inhibitors
• Antifibrotic agents
• Antihistamines
• Endothelin (ET) receptor antagonist
• Prostacyclin analogs
• Phosphodiesterase inhibitors
• Soluble guanylate cyclase (sGC) stimulators

PART 09: Market segmentation by disease
• Global asthma drugs market
• Global COPD drugs market
• Global allergic rhinitis drugs market
• Global pulmonary hypertension drugs market
• Global cystic fibrosis drugs market
• Global IPF drugs market

PART 10: Geographical segmentation
• Global respiratory drugs market by geography 2015-2020
• Respiratory drugs market in Americas
• Respiratory drugs market in EMEA
• Respiratory drugs market in APAC

PART 11: Market drivers
• Promising late-stage pipeline molecules
• Rise in prevalence of respiratory diseases
• Increase in older adult population
• High usage of tobacco
• Increase in environmental pollution

PART 12: Impact of drivers

PART 13: Market challenges
• Multiple patent expiries
• Unknown etiology of asthma and IPF
• Low diagnosis rates
• Adverse effects of drugs
• Increased preference for CAM

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Increasing awareness about respiratory diseases
• Patient assistance programs
• Usage of biologics
• Self-medication using OTC products
• Strategic alliances

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AstraZeneca
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
• Novartis
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Objectives of asthma management
Exhibit 03: COPD: Prevalence in six EU countries
Exhibit 04: Management of COPD
Exhibit 05: Prevalence rate of allergic rhinitis in China
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Prevalence of cystic fibrosis by country 2014
Exhibit 09: Treatment options for IPF
Exhibit 10: Drugs approved by US FDA for respiratory diseases 2000-2015
Exhibit 11: Pipeline portfolio of major drug candidates for respiratory diseases
Exhibit 12: Global respiratory drugs market 2015-2020 ($ billions)
Exhibit 13: Global respiratory drugs market by diseases 2015
Exhibit 14: Five forces analysis
Exhibit 15: Global asthma drugs market 2015-2020 ($ billions)
Exhibit 16: Key drivers and challenges of global asthma drugs market
Exhibit 17: Global asthma drugs market by class of drugs 2015
Exhibit 18: Global COPD drugs market 2015-2020 ($ billions)
Exhibit 19: Key drivers and challenges of global COPD drugs market
Exhibit 20: Global COPD drugs market by class of drugs 2015
Exhibit 21: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 22: Key drivers and challenges of global allergic rhinitis drugs market
Exhibit 23: Global allergic rhinitis drugs market by class of drugs 2015
Exhibit 24: Global pulmonary hypertension drugs market 2015-2020 ($ billions)
Exhibit 25: Key drivers and challenges for global pulmonary hypertension drugs market
Exhibit 26: Global pulmonary hypertension drugs market by class of drugs 2015
Exhibit 27: Global cystic fibrosis drugs market 2015-2020 ($ billions)
Exhibit 28: Key drivers and challenges for global cystic fibrosis drugs market
Exhibit 29: Global cystic fibrosis drugs market by type of molecule 2015
Exhibit 30: Global IPF market 2015-2020 ($ billions)
Exhibit 31: Key drivers and challenges for global IPF drugs market
Exhibit 32: Global respiratory drugs market: YoY revenue and growth based on respiratory diseases 2015-2020
Exhibit 33: Global respiratory drugs market by geography 2015
Exhibit 34: Global respiratory drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 35: Respiratory drugs market in Americas 2015-2020 ($ billions)
Exhibit 36: Respiratory drugs market in EMEA 2015-2020 ($ billions)
Exhibit 37: Respiratory drugs market in APAC 2015-2020 ($ billions)
Exhibit 38: Global respiratory drugs market; YoY revenue and growth based on geography 2015-2020
Exhibit 39: Impact of drivers
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Drugs that converted from Rx to OTC
Exhibit 42: Global respiratory drugs market share analysis 2015
Exhibit 43: Top selling respiratory drugs based on their revenue in 2014
Exhibit 44: AstraZeneca: Percentage share of products sales by therapy area 2014
Exhibit 45: AstraZeneca: YoY growth and revenue of Symbicort 2012-2014 ($ billions)
Exhibit 46: AstraZeneca: YoY growth and revenue of Pulmicort 2012-2014 ($ billions)
Exhibit 47: AstraZeneca: Key takeaways
Exhibit 48: Boehringer Ingelheim: YoY growth and revenue of Spiriva 2012-2014 ($ billions)
Exhibit 49: Boehringer Ingelheim: YoY growth and revenue of Combivent 2012-2014 ($ millions)
Exhibit 50: Boehringer Ingelheim: Key takeaways
Exhibit 51: F. Hoffmann-La Roche: YoY growth and revenue of Xolair in the US 2012-2014 ($ millions)
Exhibit 52: F. Hoffmann-La Roche: YoY growth and revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 53: F. Hoffmann-La Roche: Key takeaways
Exhibit 54: GlaxoSmithKline: Percentage share of products sales by therapy area 2014
Exhibit 55: GlaxoSmithKline: YoY growth and revenue of Seretide/Advair 2012-2014 ($ billions)
Exhibit 56: GlaxoSmithKline: YoY growth and revenue of Flixotide/Flovent 2012-2014 ($ billions)
Exhibit 57: GlaxoSmithKline: YoY growth and revenue of Ventolin 2012-2014 ($ billions)
Exhibit 58: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 59: GlaxoSmithKline: YoY revenue of Avamys/Veramyst 2013 and 2014 ($ millions)
Exhibit 60: GlaxoSmithKline: Key takeaways
Exhibit 61: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)1
Exhibit 62: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)2
Exhibit 63: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)2
Exhibit 64: Merck: Key takeaways4
Exhibit 65: Novartis: YoY growth and revenue of Xolair (outside the US) 2012-2014 ($ millions)6
Exhibit 66: Novartis: YoY growth and revenue of TOBI 2012-2014 ($ millions)6
Exhibit 67: Novartis: YoY growth and revenue of Onbrez Breezhaler 2012-2014 ($ millions)7
Exhibit 68: Novartis: YoY growth and revenue of Seebri Breezhaler 2012-2014 ($ millions)7
Exhibit 69: Novartis: YoY revenue of Ultibro Breezhaler 2013 and 2014 ($ millions)8
Exhibit 70: Novartis: YoY growth and revenue of Foradil Aerolizer sold outside the US 2012-2014 ($ millions)8
Exhibit 71: Novartis: Key takeaways9


【レポート販売概要】

■ タイトル:呼吸器疾患治療薬の世界市場:喘息、COPD、アレルギー性鼻炎、肺高血圧症、嚢胞性繊維症、IPF
■ 英文:Global Respiratory Drugs Market 2016-2020
■ 発行日:2016年5月4日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8439
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。